Researchers at Stanford Medicine have unveiled a naturally occurring molecular compound that demonstrates a remarkable capacity to replicate some of the appetite-suppressing and weight-reducing effects observed with semaglutide, the active ingredient in widely recognized medications such as Ozempic and Wegovy. Crucially, preliminary investigations in animal models suggest this newly identified molecule, designated as BRP, bypasses several of the frequently reported adverse reactions associated with semaglutide, including feelings of nausea, digestive discomfort, and undesirable muscle mass depletion. This discovery opens a potential new avenue for therapeutic interventions targeting metabolic health and body weight regulation.
The unique mechanism of action for BRP sets it apart from its pharmaceutical counterparts, operating through a distinct yet related biological pathway. It selectively engages specific sets of neurons within the brain, offering a more refined approach to modulating appetite and metabolic processes. Unlike semaglutide, which interacts with receptors distributed throughout the brain and also in peripheral tissues like the gastrointestinal tract, pancreas, and other organs, BRP appears to exert its primary influence within the hypothalamus. This region of the brain serves as the central control center for regulating hunger, satiety, and overall metabolism, suggesting a more localized and potentially more targeted therapeutic effect.
The scientific journey leading to the identification of BRP was significantly accelerated by the sophisticated application of artificial intelligence. The research team leveraged AI to meticulously sift through a vast array of molecules classified as prohormones. Prohormones are essentially precursor molecules that are biologically inactive in their original form but can be enzymatically cleaved into smaller, active peptide fragments. These peptides often function as hormones, playing critical roles in regulating a multitude of physiological processes, including metabolism within the brain and throughout the body.
The inherent complexity of prohormone processing presented a substantial hurdle for traditional laboratory methodologies. Each prohormone molecule possesses multiple potential sites where it can be cut, leading to the generation of a diverse range of peptide fragments. Distinguishing the therapeutically relevant signaling peptides from the myriad of inactive byproducts generated during routine protein degradation processes proved to be an exceptionally arduous task. This challenge underscores the transformative power of computational approaches in modern biological research.
To navigate this intricate molecular landscape, the researchers strategically focused on an enzyme known as prohormone convertase 1/3. This specific enzyme is known to cleave proteins at precise locations and has been implicated in the development of obesity. A prominent and well-studied product of this enzymatic activity is glucagon-like peptide 1 (GLP-1), a hormone that plays a significant role in appetite regulation and blood glucose homeostasis. Semaglutide’s efficacy stems from its ability to functionally mimic the actions of GLP-1.
The development of a specialized computational tool, christened "Peptide Predictor," proved instrumental in streamlining the discovery process. This sophisticated algorithm was designed to analyze all approximately 20,000 human protein-coding genes, systematically identifying potential cleavage sites within prohormones that could yield bioactive peptides. The team further refined their search by prioritizing proteins that are secreted from cells, a hallmark of hormonal signaling molecules, and that possess multiple sites amenable to enzymatic cleavage. This focused approach effectively reduced the initial pool of candidates to a more manageable set of 373 prohormones warranting further investigation.
The predictive power of the algorithm was described as absolutely critical to the breakthrough. Following the algorithmic analysis, the system generated predictions for an astonishing 2,683 distinct peptides. From this extensive list, the research team selected 100 peptides, including GLP-1 itself, for rigorous experimental testing. These selected peptides were then evaluated for their impact on cultured brain cells, specifically examining their ability to influence neuronal activity.
Among the tested peptides, GLP-1 predictably demonstrated a notable increase in neuronal activity, as anticipated. However, a significantly smaller peptide, composed of a mere 12 amino acids, elicited a response that was orders of magnitude more potent. This diminutive peptide boosted neuronal activity tenfold when compared to control cells, indicating a powerful signaling capability. This remarkable peptide was subsequently named BRP, derived from its parent molecule, BPM/retinoic acid inducible neural specific 2, or BRINP2 (BRINP2-related-peptide).
Subsequent investigations involving animal models provided compelling evidence of BRP’s therapeutic potential. In studies conducted with lean mice and minipigs, the latter chosen for their metabolic and eating patterns that more closely resemble those of humans, BRP demonstrated a marked reduction in food consumption. A single administration of BRP prior to a feeding session resulted in a decrease in intake of up to 50% within a single hour.
When tested in obese mouse models, a regimen of daily BRP injections administered over a 14-day period led to an average weight loss of 3 grams, with the majority of this loss attributed to a reduction in body fat. In stark contrast, untreated obese mice experienced an average weight gain of approximately 3 grams during the same experimental timeframe. Furthermore, the animals receiving BRP exhibited notable improvements in their glucose and insulin tolerance profiles, suggesting broader metabolic benefits.
A critical aspect of these findings is the apparent absence of adverse effects. The animals treated with BRP did not display any alterations in their motor activity, water intake, anxiety-related behaviors, or digestive function. Comprehensive analyses further corroborated that BRP operates through distinct neural and metabolic pathways compared to GLP-1 or semaglutide, reinforcing its unique pharmacological profile.
The research team is now actively engaged in elucidating the precise receptors that BRP interacts with and gaining a more profound understanding of its intricate mechanisms of action within the body. Efforts are also underway to explore strategies for extending the duration of BRP’s effects, which would be crucial for developing a convenient and effective therapeutic agent for human use, should it prove successful in clinical trials.
The persistent challenge of developing effective pharmacological treatments for obesity in humans has been a long-standing issue in the medical community for decades. The observed potency of BRP in reducing appetite and body weight in preclinical studies is described as unparalleled by the researchers compared to any other compound they have previously tested. There is significant anticipation regarding the potential for BRP to demonstrate both safety and efficacy in human subjects.
This groundbreaking research was a collaborative endeavor involving scientists from esteemed institutions including the University of California, Berkeley; the University of Minnesota; and the University of British Columbia. The study received substantial financial support from the National Institutes of Health, through grants R01DK125260, P30DK116074, K99AR081618, and GM113854. Additional funding was provided by several Stanford University programs, the American Heart Association, the Carlsberg Foundation, and the Wu Tsai Human Performance Alliance. Dr. Svensson and Dr. Coassolo are listed as inventors on patent applications pertaining to BRP peptides for the treatment of metabolic disorders, and Dr. Svensson also holds a co-founder role at Merrifield Therapeutics.
About the Author
